The Discovery of Prostate-specific Membrane Antigen Ligands: The Long Road to Changes in Clinical Practice for Prostate Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41539911.
- Also identified by DOI 10.1016/j.eururo.2026.01.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate-specific membrane antigen (PSMA)-targeting strategies in prostate cancer have evolved rapidly from early antibody-based approaches to highly effective diagnostic and therapeutic agents. While PSMA remains a central benchmark in metastatic disease, biological heterogeneity and therapy resistance underscore the need for continued innovation and rational combination strategies.